For the first time, researchers have identified that inflammation – long associated with multiple sclerosis (MS) – appears to cause increased mutations that damage neurons linked to MS progression. Researchers at the Florey Institute and the University of Melbourne studied MS brain lesions, which are areas of past or ongoing brain inflammation that are visible as spots on MRI scans.
Trimtech Therapeutics closed a £25 million (US$31 million) oversubscribed seed funding round to advance its targeted protein degradation treatments for neurodegenerative and inflammatory diseases.
Transthera Biosciences Co. Ltd. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.
Researchers from Revolo Biotherapeutics Ltd. recently presented preclinical data for IRL-201104, a clinical-stage immunomodulatory peptide currently in phase II development as an intravenous treatment of eosinophilic esophagitis.
Researchers from Apogee Therapeutics Inc. and Paragon Therapeutics Inc. have reported the preclinical characterization of APG-333, a half-life extended monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a cytokine secreted by epithelial cells that acts as an alarmin in response to environmental insults.
Kyorin Pharmaceutical Co. Ltd. has out-licensed its preclinical candidate, KRP-M223, and its back-up compounds to Novartis Pharma AG in a deal worth up to $777.5 million. Under the terms, Novartis gains an exclusive worldwide license to develop, manufacture and commercialize Kyorin-discovered KRP-M223.
Sanofi SA has described Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, pain, dermatological and inflammatory disorders.
Researchers from Ileadbms Co. Ltd. presented the discovery and preclinical characterization of IL-21120033, a new CXCR7 agonist being developed for the treatment of inflammatory bowel disease.
Researchers from CJ Bioscience Inc. presented the discovery and preclinical characterization of CJRB-201, a novel microbiome-based therapy for the treatment of inflammatory bowel disease (IBD).
Scientists from the Lebanese American University investigated the role of acetyl-CoA synthetase short chain family member 2 (ACSS2) in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
RSS
